James Cain, MD
Family Medicine · Lampasas, TXNPI 1467434464
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 71.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $5,992 and has fallen 96.7% since, to $195 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $44.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Novo Nordisk$484
- AbbVie$344
- Dexcom, Inc.$187
- Lilly USA, LLC$116
- AstraZeneca$107
- plus $1K from 25 others
Across 1,317 payments — averaging $2241.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1M
- Pfizer$637K
- Sanofi Pasteur Inc.$296K
- Merck$264K
- Supernus Pharmaceuticals, Inc.$180K
- AstraZeneca$130K
- plus $406K from 12 others
What the payments were for
- Consulting fees$4,55054%
- Travel & lodging$80610%
- Food & beverage$3,01536%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 34 | $6,034 |
| Novo Nordisk | 32 | $484 |
| AbbVie(2 entities) | 22 | $344 |
| Dexcom, Inc. | 12 | $187 |
| Lilly USA, LLC | 8 | $116 |
| AstraZeneca | 8 | $107 |
| GSK | 7 | $104 |
| Corium, LLC | 4 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Merck | 8 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $79 |
| Boehringer Ingelheim | 4 | $76 |
| Amgen | 5 | $65 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Novartis | 3 | $45 |
| Abbott | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $17 |
| Mission Pharmacal Company | 1 | $15 |
| Valeritas, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Biogen | 1 | $14 |
| Cranial Technologies, Inc | 1 | $14 |
| Tris Pharma Inc | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$8,389 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $148,950 |
| MounjaroTirzepatide | 71 | $76,426 |
| EliquisApixaban | 61 | $43,434 |
| JanuviaSitagliptin Phosphate | 52 | $42,123 |
| TrulicityDulaglutide | 29 | $36,123 |
| JardianceEmpagliflozin | 20 | $25,890 |
| XareltoRivaroxaban | 25 | $21,511 |
| MyrbetriqMirabegron | 22 | $16,153 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $6,883 |
| Atorvastatin Calcium | 482 | $6,134 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $4,134 |
| Levemir FlexpenInsulin Detemir | 17 | $3,681 |
| Omeprazole | 233 | $3,643 |
| Tamsulosin Hcl | 140 | $3,434 |
| Levothyroxine Sodium | 315 | $3,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $484 | $148,950111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $112,550100 claims |
| PfizerEliquis | $6,034 | $43,43461 claims |
| MerckJanuvia | $82 | $42,12352 claims |
| Boehringer IngelheimJardiance | $76 | $25,89020 claims |
| Johnson & JohnsonXarelto | $11 | $21,51125 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $4,13415 claims |
| AbbVieSynthroid | $344 | $1,88818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lampasas
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.